EKF Diagnostics Holdings plc
("EKF" or the "Company")
Notice of Interim Results and Investor Presentation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, will announce its interim results for the six months ended 30 June 2024 on Tuesday 17 September 2024.
Investor Presentation
Julian Baines, Executive Chair, and Stephen Young, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company (IMC) platform at 4.30pm (BST) on Wednesday 18 September 2024. The presentation is open to all existing and potential investors.
Investors can sign up to IMC for free and register for the presentation here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.
A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.
| EKF Diagnostics Holdings plc | |||
| Julian Baines, Executive Chair / Stephen Young, CFO | via Walbrook PR | ||
| | | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | ||
| Phil Davies / Oliver Platts | | ||
| | | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | ||
| Paul McManus / Charlotte Edgar | | ||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
| ā | Point-of-Care analysers in the key areas of Hematology and Diabetes |
| ā | Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.